The most significant effect of two polymorphisms in the MAPK1 gene, and the presence of four of the five adverse alleles in the MAPK1, CDCP1, TFRC, and DEC1 gene set, was a more than twofold increase in the risk of RCC. The gene discussed is CDCP1; the disease is renal cell carcinoma.